Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy aloneMichael Gnant, Torsten O. Nielsen, Martin Filipits et al.|Annals of Oncology|2013Cited by 403
The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast CancerMartin Filipits, Herbert Stöger, R. Jakesz et al.|Clinical Cancer Research|2014Cited by 219
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)Christian F. Singer, Michael Gnant, Georg Pfeiler et al.|European Journal of Cancer|2020Cited by 52
The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2− early breast cancerRuth Exner, Peter Dubsky, Zsuzsanna Bagó-Horváth et al.|British Journal of Cancer|2014Cited by 38
Abstract S2-06: Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 studyMichael Knauer, Michael Gnant, Christine Gruber et al.|Cancer Research|2015Cited by 21